PBS Biotech has integrated Rockwell Automation technology into its MiniPRO™ multi-parallel bioreactor platform to accelerate cell therapy process development and ease scale-up to commercial manufacturing. This platform offers up to 24 independently controlled bioreactors with real-time process control, enabling reproducibility and regulatory readiness. The use of standardized automation helps reduce variability and risk, supporting smoother tech transfer from development to clinical and commercial production. Early adopters like the Advanced Regenerative Manufacturing Institute highlight the system's ease of integration and scalability for larger manufacturing lines.
Rockwell Automation (ROK) holds a market cap of $47.89 billion and a dividend yield of 1.28%, with a typical hold time of 73 days on Pluang as of September 29, 2026, 22:11 WIB. The stock price is $430.07, down slightly by 0.27% on the day. This stable market presence complements Rockwell Automation's role in advancing industrial automation technologies, such as the integration with PBS Biotech's cell therapy platform.
